SKB BIO-B: VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR CORE PRODUCT SACITUZUMAB TIRUMOTECAN (SAC-TMT) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

HKEX · Aug 19 20:51

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.